Intellia Therapeutics CEO John M. Leonard Sells 34,146 Shares for $314,484
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: NASDAQ.COM
- Insider Selling: On January 5, Intellia Therapeutics CEO John M. Leonard sold 34,146 shares directly held, totaling $314,484.66, representing 3.09% of his direct holdings, indicating a selling pattern during a period of uncertainty for the company.
- Ownership Status: Post-transaction, Leonard retains over 1 million shares directly and more than 58,000 shares indirectly through an irrevocable trust, reflecting his ongoing commitment to Intellia's long-term prospects.
- Financial Health: As of Q3, Intellia reported approximately $670 million in cash and marketable securities, sufficient to fund operations into mid-2027, while effectively managing costs reduced net losses from $135.7 million to $101.3 million despite clinical uncertainties.
- Market Implications: While insider selling may raise concerns, the focus should be on the capital-intensive phase and the significant risks associated with regulatory setbacks and pipeline execution, making short-term stock movements less critical.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTLA is 15.97 USD with a low forecast of 4.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 11.430
Low
4.00
Averages
15.97
High
54.00
Current: 11.430
Low
4.00
Averages
15.97
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
